Summary
Antibody-mediated rejection (AMR) is the leading cause of graft failure. While donor-specific antibodies (DSA) are associated with a higher risk of AMR, not all patients with DSA develop rejection suggesting that the characteristics of alloantibodies that determine their pathogenicity remain undefined. Using human leukocyte antigen (HLA)-A2-specific antibodies as a model, we applied systems serology tools to investigate qualitative features of immunoglobulin G (IgG) alloantibodies including Fc-glycosylation patterns and FcγR binding properties. The levels of afucosylation of anti-A2 antibodies were elevated in all seropositive patients and were significantly higher in AMR patients, suggesting potential cytotoxicity via FcγRIII-mediated mechanisms. Afucosylation of both glycoengineered monoclonal and naturally glycovariant polyclonal serum IgG specific to HLA-A2 exhibited potentiated binding to, slower dissociation from, and enhanced signaling through FcγRIII, a receptor widely expressed on innate effector cells. Collectively, these results suggest that afucosylated DSA may be a biomarker of AMR and could contribute to its pathogenesis.
Illustration created with https://BioRender.com.
Competing Interest Statement
PB, SS, TP, ALM, NdeH, MW, AM, and MEA are named inventors on a provisional patent application related to this work.
Funding Statement
Variably fucosylated IgG was produced by the Dartmouth bioMT- Institute for Biomolecular Targeting (NIGMS COBRE award P20-GM113132). T. P. has received funding from the European Union Horizon 2020 Research and Innovation Programme under H2020-MSCA-ITN grant agreement number 721815. C.C has received funding from the Fonds National de la Recherche Scientifique (FNRS) Belgium and from the Fonds Erasme Belgium.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Review Board of the Hopital Erasme, Brussels, Belgium gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Share first authorship
Data Availability
Data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- ADCC
- Antibody-dependent cellular cytotoxicity
- AMR
- Acute-mediated rejection
- BLI
- Biolayer Interferometry
- DSA
- Donor specific antibody
- Fc
- Fragment crystallizable
- HLA
- Human leukocyte antigen
- IgG
- Immunoglobulin G
- IVIG
- Intravenous immunoglobulin
- G MFI
- Mean Fluorescent Intensity
- R
- receptor